Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wouter A P Breeman

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
International Journal of Cancer|February 6, 2003
Anti-tumor effect and increased survival after treatment with [177Lu-DOTA0,Tyr3]octreotate in a rat liver micrometastases modelWouter A P Breeman, Amir Mearadji, Astrid Capello, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 7, 2002
The inhibitory effect of (111)In-DTPA(0)-octreotide on intrahepatic tumor growth after partial hepatectomyGerrit D Slooter, Arend G J Aalbers, Wouter A P Breeman, et al.
EJNMMI Radiopharmacy and Chemistry|March 23, 2018
Optimizing labelling conditions of <sup>213</sup>Bi-DOTATATE for preclinical applications of peptide receptor targeted alpha therapyHo Sze Chan, Erik de Blois, Mark W Konijnenberg, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 29, 2003
The addition of DTPA to [177Lu-DOTA0,Tyr3]octreotate prior to administration reduces rat skeleton uptake of radioactivityWouter A P Breeman, Katy van der Wansem, Bert F Bernard, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 7, 2002
Preclinical comparison of (111)In-labeled DTPA- or DOTA-bombesin analogs for receptor-targeted scintigraphy and radionuclide therapyWouter A P Breeman, Marion de Jong, Jack L Erion, et al.
Journal of Medicinal Chemistry|January 10, 2008
Lanthanide(III) complexes of bis(phosphonate) monoamide analogues of DOTA: bone-seeking agents for imaging and therapyTomás Vitha, Vojtech Kubícek, Petr Hermann, et al.
Cancer Biotherapy & Radiopharmaceuticals|July 27, 2007
Five Stabilized 111In-labeled neurotensin analogs in nude mice bearing HT29 tumorsPaul J J M Janssen, Moniaue de Visser, Suzanne M Verwijnen, et al.
Nuclear Medicine and Biology|November 26, 2008
Optimised labeling, preclinical and initial clinical aspects of CCK-2 receptor-targeting with 3 radiolabeled peptidesWouter A P Breeman, A C Fröberg, E de Blois, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 28, 2011
Comparison of the binding and internalization properties of 12 DOTA-coupled and ¹¹¹In-labelled CCK2/gastrin receptor binding peptides: a collaborative project under COST Action BM0607Luigi Aloj, Michela Aurilio, Valentina Rinaldi, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
International Journal of Cancer|February 6, 2003
Anti-tumor effect and increased survival after treatment with [177Lu-DOTA0,Tyr3]octreotate in a rat liver micrometastases modelWouter A P Breeman, Amir Mearadji, Astrid Capello, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 7, 2002
The inhibitory effect of (111)In-DTPA(0)-octreotide on intrahepatic tumor growth after partial hepatectomyGerrit D Slooter, Arend G J Aalbers, Wouter A P Breeman, et al.
EJNMMI Radiopharmacy and Chemistry|March 23, 2018
Optimizing labelling conditions of <sup>213</sup>Bi-DOTATATE for preclinical applications of peptide receptor targeted alpha therapyHo Sze Chan, Erik de Blois, Mark W Konijnenberg, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 29, 2003
The addition of DTPA to [177Lu-DOTA0,Tyr3]octreotate prior to administration reduces rat skeleton uptake of radioactivityWouter A P Breeman, Katy van der Wansem, Bert F Bernard, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 7, 2002
Preclinical comparison of (111)In-labeled DTPA- or DOTA-bombesin analogs for receptor-targeted scintigraphy and radionuclide therapyWouter A P Breeman, Marion de Jong, Jack L Erion, et al.
Journal of Medicinal Chemistry|January 10, 2008
Lanthanide(III) complexes of bis(phosphonate) monoamide analogues of DOTA: bone-seeking agents for imaging and therapyTomás Vitha, Vojtech Kubícek, Petr Hermann, et al.
Cancer Biotherapy & Radiopharmaceuticals|July 27, 2007
Five Stabilized 111In-labeled neurotensin analogs in nude mice bearing HT29 tumorsPaul J J M Janssen, Moniaue de Visser, Suzanne M Verwijnen, et al.
Nuclear Medicine and Biology|November 26, 2008
Optimised labeling, preclinical and initial clinical aspects of CCK-2 receptor-targeting with 3 radiolabeled peptidesWouter A P Breeman, A C Fröberg, E de Blois, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 28, 2011
Comparison of the binding and internalization properties of 12 DOTA-coupled and ¹¹¹In-labelled CCK2/gastrin receptor binding peptides: a collaborative project under COST Action BM0607Luigi Aloj, Michela Aurilio, Valentina Rinaldi, et al.
Pageof 3